J Bacteriol 2006,188(19):6719–6727.PubMedCentralPubMedCrossRef 35. Singh H, Schuermann JP, Reilly TJ, Calcutt MJ, Tanner JJ: Recognition of nucleoside monophosphate substrates by Haemophilus influenzae class C acid phosphatase. CP673451 datasheet J Mol Biol 2010,404(4):639–649.PubMedCentralPubMedCrossRef 36. Sauer E, Merdanovic M, Mortimer AP, Bringmann G, Reidl J: PnuC and the utilization of the nicotinamide riboside analog 3-aminopyridine in Haemophilus influenzae . Antimicrob Agents Chemother 2004,48(12):4532–4541.PubMedCentralPubMedCrossRef

37. Kurnasov OV, Polanuyer BM, Ananta S, Sloutsky R, Tam A, Gerdes SY, Osterman AL: Ribosylnicotinamide kinase domain of NadR protein: identification and implications in NAD biosynthesis. J Bacteriol 2002,184(24):6906–6917.PubMedCentralPubMedCrossRef 38. Martin

PR, Shea RJ, Mulks MH: Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence. J Bacteriol 2001,183(4):1168–1174.PubMedCentralPubMedCrossRef 39. Munson RS Jr, Zhong H, Mungur R, Ray WC, Shea RJ, Mahairas GG, Mulks MH: Haemophilus ducreyi strain ATCC 27722 contains a genetic element with homology to the vibrio RS1 element that can replicate as a plasmid and confer NAD independence this website on Haemophilus influenzae . Infect Immun 2004, 72:1143–1146.PubMedCentralPubMedCrossRef 40. Al-Tawfiq JA, Thornton AC, Katz BP, Fortney KR, Todd KD, Hood AF, Spinola SM: Standardization of the experimental model of Haemophilus ducreyi infection in human subjects. J Infect Dis 1998, 178:1684–1687.PubMedCrossRef 41. Menard R, Sansonetti PJ, Parsot C: Nonpolar mutagenesis of the ipa genes defines IpaB, IpaC, and IpaD as effectors of Shigella flexneri entry into epithelial cells. J Bacteriol 1993, 175:5899–5906.PubMedCentralPubMed 42. Bozue JA, Tarantino L, Munson RS Jr: Facile construction of mutations in Haemophilus ducreyi using lacz as a counter-selectable marker. FEMS Microbiol

Lett 1998, 164:269–273.PubMedCrossRef 43. Spinola SM, Bong CT, Faber AL, Fortney KR, Bennett SL, Townsend CA, Zwickl BE, Billings SD, Humphreys TL, Bauer ME, Katz BP: Differences Selleck Atezolizumab in host susceptibility to disease progression in the human challenge model of Haemophilus ducreyi infection. Infect Immun 2003,71(11):6658–6663.PubMedCentralPubMedCrossRef 44. Banks KE, Fortney KR, Baker B, Billings SD, Katz BP, Munson RS Jr, Spinola SM: The enterobacterial common antigen-like gene cluster of Haemophilus ducreyi contributes to virulence in humans. J Infect Dis 2008, 197:1531–1536.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions DMJ conceived and designed the study, https://www.selleckchem.com/products/chir-99021-ct99021-hcl.html carried out the in vitro work, directed the human challenge studies, and drafted the manuscript. BWZ carried out the clinical component of the human challenge studies. KRF carried out the in vitro component of the human challenge studies and participated in the bactericidal assays.